Patent ID: 11912781
Assignee: VISTERRA, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating a C5a/C5aR1 mediated autoimmune disease, comprising administering an antibody or an antigen binding fragment thereof to a subject in need of the treatment, wherein the antibody or the antigen binding fragment thereof binds complement component 5a receptor 1 (C5aR1) and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises three heavy chain complementarity determining regions (HCDRs), wherein the HCDR1, HCDR2 and HCDR3 comprise SEQ ID NO: 6 (NYWMH), SEQ ID NO: 7 (YLNPSSGYTKYAQKFQG), and SEQ ID NO: 8 (SGGDNYGNPY YFDR), respectively, wherein the VL comprises three light chain complementary determining regions (LCDRs), wherein the LCDR1, LCDR2, and LCDR3 comprise SEQ ID NO: 9 (RASQSIVHSNGNTYLH), SEQ ID NO: 10 (KVSNRES), SEQ ID NO: 11 (AQYTLVPLT), respectively.